Quick Answer
ProQR Therapeutics N.V. reported R&D Expense of $44.73 million for fiscal year 2025.
ProQR Therapeutics N.V. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $44.73M | +23.0% |
| 2024 | $36.36M | +44.6% |
| 2023 | $25.15M | -50.6% |
| 2022 | $50.87M | +20.5% |
| 2021 | $42.22M | +10.7% |
| 2020 | $38.13M | -18.0% |
| 2019 | $46.49M | +57.5% |
| 2018 | $29.51M | -5.3% |
| 2017 | $31.15M | -2.4% |
| 2016 | $31.92M | +36.4% |
| 2015 | $23.40M | — |
- ProQR Therapeutics N.V. showed an increase of +23.0% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, ProQR Therapeutics N.V.’s r&d expense has grown by 91.2% (from $23.40 million to $44.73 million).
- The most recent figure is from ProQR Therapeutics N.V.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: